Albuminuria and incident coronary heart disease in Australian Aboriginal people  by Wang, Zhiqiang & Hoy, Wendy E.
Kidney International, Vol. 68 (2005), pp. 1289–1293
Albuminuria and incident coronary heart disease in Australian
Aboriginal people
ZHIQIANG WANG and WENDY E. HOY
Centre for Chronic Disease, School of Medicine, The University of Queensland, Brisbane, Queensland, Australia
Albuminuria and incident coronary heart disease in Australian
Aboriginal people.
Background. It has been suggested that albuminuria is useful
in identifying persons at increased risk of coronary heart dis-
ease (CHD). Australian Aborigines have exceedingly high rates
of renal failure together with increased CHD mortality. We un-
dertook this prospective cohort study to assess the independent
effect of albuminuria on CHD risk in Aboriginal people in the
Northern Territory of Australia.
Methods. We examined the relation between micro- and
macroalbuminuria and incident CHD in a sample of 870 Abo-
riginal adults aged 20 to74 years old without prevalent baseline
CHD. Cox proportional hazards models were used to assess the
association between baseline albuminuria and CHD incidence.
Results. During a median of 9.2 years of follow-up, 89 CHD
events occurred during the follow-up period (1992 to 2003). The
incidence of CHD increased significantly across categories of
albuminuria (4.4, 10.9, and 29.8 per 1000 person-years for nor-
moalbuminuria, microalbuminuria, and macroalbuminuria, re-
spectively). The multiple Cox proportional hazards regression
showed the hazard ratio was 3.4 (95% CI 1.6, 7.3), adjusting
for age, gender, body mass index (BMI), blood pressure, to-
tal cholesterol, diabetes status, cigarette smoking, and alcohol
consumption, for macroalbuminuria group. Hazard ratio for mi-
croalbuminuria group was not significantly different from unity
during the first 6 years of follow-up but significantly higher dur-
ing the follow-up period ≥6 years with adjusted hazard ratio 9.0
(95% CI 2.0, 40.0).
Conclusion. Independent of traditional cardiovascular risk
factors, both microalbuminuria and macroalbuminuria may be
useful in identifying persons at increased risk of CHD in Abo-
riginal people.
Aboriginal Australians have a high rate of end-stage
of renal disease (ESRD) together with increased cardio-
vascular mortality [1]. They also have higher prevalence
of albuminuria than Australians of European descent [2].
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An association between albuminuria and subsequent car-
diovascular mortality in Aboriginal people was demon-
strated [3]. Cross-sectional studies showed a powerful
association between albuminuria and cardiovascular risk
factors [4–6]. It has been found in non-Aboriginal popu-
lations that any degree of albuminuria is a risk factor for
cardiovascular events in diabetic and nondiabetic individ-
uals [7]. Microalbuminuria is useful in identifying persons
at increased risk of coronary heart disease (CHD) in the
general British population [8].
Although the significance of albuminuria as a possi-
ble predictor of CHD has been suggested [6, 9], there
has not been a cohort study of albuminuria and incident
CHD in Aboriginal people. It is not clear if the associa-
tion between albuminuria and CHD risk is independent
of the traditional risk factors this population. Therefore,
we undertook this prospective study, with a median of
9.2 years of follow-up, to examine the relationship be-
tween albuminuria levels and future CHD events.
METHODS
From 1992 to 1995, a community-wide renal disease
screening program, involving 897 adults aged 20 to
74 years old, was conducted in a remote island commu-
nity in Northern Territory. There were 878 who had a
baseline measurement of urine albumin/creatinine ratio.
Eight participants were excluded because their hospital
records showed preexisting CHD events. Thus, 870 peo-
ple representing over 80% the adult population in the
community were included in this study.
Measurements
The urinary albumin and creatinine concentrations
were measured on a random urine specimen. Urinary
albumin concentration was measured by the Beckman
immunoassay (Beckman Instruments, Fullerton, CA,
USA). An albumin:creatinine ratio (ACR) was calcu-
lated (mg/mmol). Previous studies in Aboriginal people
used 3.4 mg/mmol and 34 mg/mmol as cutoffs for micro-
and macro- (or overt) albuminuria [3–6]. Other studies
defined microalbuminuria as an ACR of 2.0 mg/mmol
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Table 1. Baseline characteristics of study participants by categories of albuminuria
Albumin:creatinine ratio (ACR) category
Normoalbuminuria Microalbuminuria Macroalbuminuria
0.00–2.49 mg/mmol 2.50–25.0 mg/mmol >25 mg/mmol P value
Number (%) 389 (45) 265 (30) 216 (25)
Age years 30.3 (10.2) 34.5 (11.8) 41.6 (12.3) <0.001
Body mass index kg/m2a 22.3 (4.7) 24.4 (5.2) 26.1 (5.7) <0.001
Total cholesterol mmol/La 4.4 (1.0) 4.7 (1.0) 5.2 (1.3) <0.001
Systolic pressure mm Hga 116.5 (16.4) 122.0 (16.5) 130.5 (20.8) <0.001
Diastolic pressure mm Hga 70.5 (11.4) 75.2 (13.2) 81.6 (15.2) <0.001
Urine ACR mg/mmolb 0.7 (0.7, 0.8) 7.3 (6.7, 7.9) 84.1 (75.8, 93.3) <0.001
Triglycerides mmol/Lb 1.6 (1.5,1.7) 1.9 (1.8, 2.0) 2.5 (2.3, 2.8) <0.001
Male (%) 209 (53.7) 142 (53.6) 91 (42.1) 0.0132
Smoking (%) 294 (75.6) 186 (70.2) 148 (68.5) 0.1223
Drinking (%) 225 (57.8) 157 (59.2) 109 (50.5) 0.1166
Diabetes (%) 20 (5.1) 27 (10.2) 71 (32.9) <0.001
aMean (SD).
bGeometric mean (95% CI).
[7]. However, to be consistent with recent cohort stud-
ies on predictive values of albuminuria on heart disease,
this study defined normoalbuminuria as an ACR less
than 2.5 mg/mmol, microalbuminuria as an ACR 2.5 to
25 mg/mmol, and macroalbuminuria as an ACR greater
than 25 mg/mmol [8, 10, 11]. CHD risk factors such as
blood pressures, serum cholesterol, triglycerides, body
mass index (BMI), cigarette smoking, alcohol drinking,
and the presence of diabetes were described elsewhere
[12–14].
CHD
We identified fatal and nonfatal CHD events occurring
between baseline and follow-up through December 31,
2003. CHD events were defined from hospital and death
records using the codes of Internationl Classification of
Diseases, Ninth edition (ICD-9-CM) codes 410–414 and
ICD-10-AM codes I20-I25. Hospital Registration Num-
bers were used to link CHD events with baseline data.
Statistical analysis
CHD incidence rates were calculated by dividing the
number of first-ever CHD events by the person-years of
follow-up according to the three categories of albumin-
uria. Hazard ratios and their 95% CIs were estimated
using the Cox proportional hazards model, adjusting for
potential confounding factors of (1) age and gender and
(2) age, gender, smoking, alcohol drinking, blood pres-
sure, BMI, serum cholesterol, and diabetes status.
In a subset of study sample, 598 participants had at
least one subsequent urine ACR measurements from 1
to 5 years after the initial measurement. To understand
how well the baseline ACR measurement can reflect the
usual ACR level during the follow-up period, correla-
tion coefficients between initial measurement and subse-
quent measurements were calculated. All analyses were
performed using Stata version 8 [15].
Table 2. Pearson correlation coefficients between baseline
albumin:creatinine ratio (ACR) and follow-up ACRs
Time after baseline Correlation coefficients Number
ACR year 1 0.8278 306
ACR year 2 0.7959 220
ACR year 3 0.7631 280
ACR year 4 0.7392 213
ACR year 5+ 0.6412 146
Ethics approval
The project was approved by the Behavioural and
Social Science Ethical Review Committee of the Univer-
sity of Queensland, the Human Research Ethics Com-
mittee of the Northern Territory Department of Health
and Community Services and Menzies School of Health
Research, and the community health board.
RESULTS
Baseline characteristics
Thirty percent of participants had microalbuminuria
and 25% had macroalbuminuria. Table 1 shows baseline
characteristics of the study population by categories of al-
buminuria. Albuminuria was significantly associated with
a number of cardiovascular risk factors, including age,
blood pressure, total cholesterol, BMI, triglycerides, and
diabetes.
Correlations between baseline and subsequent
measurements
Based on a convenient sample, the baseline ACR
measurement was significantly correlated with follow-up
ACR measurements. The correlation decreased with the
duration of follow-up from 0.83 at year 1 to 0.64 at year
5 after the baseline measurement (Table 2).
Wang and Hoy: Albuminuria and CHD in Australian Aboriginal people 1291
Table 3. Incidence of coronary heart disease (CHD) by categories of
albuminuria in Aboriginal people
CHD Person- Incidence (95% CI)/
Albuminuria events years 1000 person-years
Normal 15 3426.7 4.4 (2.6, 7.3)
Micro 25 2297.6 10.9 (7.4, 16.1)
Macro 49 1645.1 30.0 (22.5, 39.4)
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Fig. 1. Albuminuria and coronary heart disease (CHD) incidence in
Aboriginal Australians.
Association between albuminuria and CHD
A total of 89 CHD events occurred during a median of
9.2 years in 870 participants. Fifty one (57%) participants
had acute myocardial infarction and 26 (29%) had angina
pectoris. As is shown in Table 3 and Figure 1, the incidence
of CHD increased significantly across categories of base-
line albuminuria. After adjusting for age and gender with
normoalbuminuria as the reference group, the CHD risk
was about doubled for microalbuminuria and about four-
fold for macroalbuminuria during the whole follow-up
period (Table 4). The increased CHD risk for microal-
buminuria and macroalbuminuria groups remained af-
ter adjustment for major CHD risk factors including age,
gender, BMI, blood pressure, total cholesterol, diabetes
status, cigarette smoking, and alcohol consumption. The
risk of CHD for microalbuminuria group increased dra-
matically after 6 years. We divided the follow-up time into
two periods: <6 years and ≥6 years. The interaction term
between follow-up time and microalbuminuria was found
to be statistically significant. Therefore, the hazard ratios
for two time periods are presented in Table 4. The haz-
ard ratio 0.96 (0.34, 2.7) for microalbuminuria group was
not significantly different from unity during early follow-
up period although it was significantly higher during the
period ≥6 years (Table 4).
DISCUSSION
A growing number of epidemiologic studies have re-
ported that microalbuminuria is a strong risk factor of
cardiovascular disease [7, 8, 16–20]. This study confirmed
that the incidence of CHD increased significantly across
categories of baseline albuminuria in Aboriginal peo-
ple. Microalbuminuria and macroalbuminuria were in-
dependently associated with an increased risk of CHD in
comparison with normoalbuminuria. Therefore, microal-
buminuria and macroabuminuria may be useful indica-
tors, in addition to conventional risk factors such as age
gender, smoking, total cholesterol, blood pressure, BMI,
and diabetes, in identifying persons who are at increased
risk of primary CHD.
The data are consistent with previous studies in Abo-
riginal populations which showed albuminuria associated
with cardiovascular risk factors [4, 5, 12, 21]. Our prospec-
tive data indicate that the contribution of albuminuria
to CHD risk is independent of traditional risk factors.
Microalbuminuria was found to be an independent pre-
dictor of CHD risk in the general British population in
the EPIC-Norfolk Study [8], and in a sample from North
America, South America and Europe in the Heart Out-
comes Prevention Evaluation (HOPE) study [7].
Our study participants had a higher prevalence of al-
buminuria than other published data. We found 30%
microalbuminuria and 25% macroalbuminuria in our
study sample while in the British population there are
only 11.6% microalbuminuria and 0.8% macroalbumin-
uria [8]. An Australian study has shown that Aboriginal
Australians have a higher prevalence of albuminuria than
Australians of European decent [2]. However, the associ-
ation between albuminuria and CHD risk in Aboriginal
people in this study is consistent with findings in other
populations. The age- and gender-adjusted hazard ratio
for CHD associated with microalbuminuria for the over-
all follow-up period is 1.98 (95% CI 1.04, 3.79) in our
study while the corresponding ratio is 1.65 for British
population [8]. The hazards ratio for major cardiovascu-
lar events associated with microalbuminuria in the HOPE
study is 1.83 [7]. Although similar relative risks have
been found across different populations, microalbumin-
uria may play a more important role in Aboriginal popu-
lation due to its higher prevalence of microalbuminuria.
Some limitations of this study should be pointed out.
First, the CHD events were identified through hospital
inpatient and death records. Some minor CHD events
not severe enough for hospitalization may have been
missed. Second, the risk of albuminuria measured on a
single occasion at baseline tends to underestimate the
true association between “usual” albuminuria level and
CHD. Regression dilution bias is one of concerns for
using baseline risk values in cohort studies with a long
period of follow-up [22–24]. The magnitude of regres-
sion dilution increases with increasing length of follow-up
[24]. The correlation coefficients between baseline mea-
surement and resurveyed values have been used to assess
the magnitude of the bias [24]. The correlation coefficient
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Table 4. Hazard ratios (95% CI) for coronary heart disease (CHD) by categories of albuminuria in Aboriginal people
Overall follow-up period Follow-up time <6 years Follow-up time ≥6 years
Albuminuria HRa HRb HRa HRb HRa HRb
Normal 1 1 1 1 1 1
Micro 2.0 (1.04, 3.8) 2.6 (1.2, 5.5) 0.68 (0.27, 1.7) 0.96 (0.34 2.7) 7.3 (2.1, 25.2) 9.0 (2.0, 40.0)
Macro 3.9 (2.1, 7.2) 3.4 (1.6, 7.3) 3.5 (1.8, 7.0) 2.9 (1.2, 7.0) 5.1 (1.4, 18.8) 4.9 (1.0, 24.8)
Body mass index, blood pressure, and total cholesterol were continuous variables. Diabetes status, cigarette smoking and alcohol consumption were dichotomous.
aAdjusting for age and gender.
bAdjusting for age, gender, body mass index, blood pressure, total cholesterol, diabetes status, cigarette smoking, and alcohol consumption.
for ACR between baseline and year 5 (r = 0.64) is sim-
ilar to those for systolic and diastolic blood pressures in
Framingham and MONICA data [24]. Therefore, the
presence of dilution bias tends to underestimate the true
association between albuminuria and CHD risk. Third,
a subset of study participants with ACR ≥34 g/mol or
diabetes and ACR ≥3.4 g/mol received an angiotensin-
converting enzyme (ACE) inhibitor (perindopril) treat-
ment during the follow-up period. [25] Due to the
beneficial effects of ACE inhibitor and the fact that the
treatment mostly occurred in albuminuria groups,[25] the
incidence of CHD could have been higher in albuminuria
groups if the treatment had not been used in this popula-
tion. Therefore, the use of ACE inhibitors among study
participants might have diluted the true association be-
tween albuminuria and CHD. Fourth, although the mi-
croalbuminuria group had an increased CHD incidence
than the normal group during the overall follow-up pe-
riod, the significant difference only appeared after 6 years
of follow-up. It remains unanswered if the progression
from micro- to macroalbuminuria during the follow-up
period contributed to this pattern.
The underlying pathophysiologic mechanism behind
the association between albuminuria and CHD is still
not clear. There are several possible explanations. Al-
buminuria is a marker of established CHD risk factors.
There is a large body of data demonstrating associa-
tions between microalbuminuria and established cardio-
vascular risk factors, including elevated blood pressure,
elevated lipid levels, adiposity, carotid intima-media
thickness, smoking, and diabetes in both Aboriginal and
other populations [4, 5, 12, 21]. In the present study we
observed an association between albuminuria and ma-
jor risk factors such as total cholesterol, blood pressure,
and diabetes. However, the association may not be me-
diated by those factors since the association remained
after adjustment of those factors. It is suggested that al-
buminuria may reflect endothelial dysfunction that might
enhance the penetration of atherogenic lipoproteins into
the arterial wall [26]. The study of Jensen [27] indicates
that atherosclerotic vascular disease is associated with re-
nal and systemic transvascular leakiness for albumin, and
such leakiness may allow for an increased lipid insudation
into the large vessel wall, thereby linking microalbumin-
uria to atherogenesis. However, Agewall and Bjorn [28]
suggested microalbuminuria in healthy subjects is not pri-
marily associated with atherosclerosis but rather to blood
pressure and abdominal obesity.
Although the true explanation of the pathophysiologic
relationship between albuminuria and CHD is still not
clear, it is important to know that microalbuminuria is
a useful independent predictor of CHD risk. Improving
kidney function may be potentially beneficial to prevent-
ing CHD in Aboriginal people. Our results suggest that
microalbuminuria and macroalbuminuria can be useful
for identifying persons at increased risk of CHD who
might benefit the most from treatment. Conventional risk
factors underestimated the risk of CHD in Aboriginal
people [29]. Albuminuria may be a useful indicator in
the absolute risk equations in addition to conventional
risk factors.
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